Overview
Fortis Pharmaceuticals is a dynamic Polish pharmaceutical company that develops high-quality health products. It offers a range of dietary supplements such as Tribiolac, Gardipect, and Solvit D3, as well as medications including Ibufast Forte and Diclogel. The company focuses on improving patient health and comfort through its diverse product line.
Financials
Revenue history (in k)
Financial insight
- Possible Estonian CIT: Equity includes Art. 28d line items, but all amounts are 0 — this may be an accounting template or the first year of the regime.
Data and insights are generated automatically based on financial statements and may contain errors. This analysis is for informational purposes only and does not constitute an official assessment of the company's credibility or business advice.
Statistics
How the company ranks by revenue within its industry, region and across Poland in 2025.
Results vs industry
Industry
Bank accounts
Registered as a VAT taxpayer on 2012-07-18. Active
08 1500 1445 1214 4008 3461 0000
19 1020 2313 0000 3202 0579 9566
69 1140 1049 0000 5061 7900 1001
Debt
No entries in the National Debtors Register (KRZ). No proceedings in KRZ
Public aid
26 public aid cases recorded, with a total value of $309,401.
| Grant date | Purpose | Gross amount | Granting body | |
|---|---|---|---|---|
| Mar 26, 2025 | De minimis aid (in accordance with Commission Regulation 2023/2831) | $21,246 | Prezes Banku Gospodarstwa Krajowego | |
| Mar 17, 2025 | De minimis aid (in accordance with Commission Regulation 2023/2831) | $1,573 | Marszałek Województwa Śląskiego | |
| Mar 26, 2024 | De minimis aid (in accordance with Commission Regulation No 1407/2013 or earlier) | $24,756 | Prezes Banku Gospodarstwa Krajowego |
Tenders
No recorded participation in tenders.
Regulatory authorisations
| Authority | Type | Status | |
|---|---|---|---|
 BDO | BDO register entry | Active |
Authorized Representatives
Manner of representation
The right and obligation to represent and conduct the affairs of the transformed company shall be vested in the management board of the transformed company, acting in accordance with the rules of representation specified by the Commercial Companies Code and the articles of association of the company operating under the business name FORTIS PHARMACEUTICALS spółka z ograniczoną odpowiedzialnością with its registered office in Katowice. The management board consists of 1 to 3 members appointed by a resolution of the meeting of partners. The management board is appointed for an indefinite period; however, the partners’ resolution appointing the management board may provide otherwise. Szymon Kamiński shall be President of the Management Board of the transformed company, and Dominik Kołodziej shall be Vice-President of the Management Board.
Ownership
| Owner | Shares | Share value | Stake |
|---|---|---|---|
Szymon Dawid Kamiński (46) | 100 | $2,701.24 | 50% |
Dominik Marcin Kołodziej (45) | 100 | $2,701.24 | 50% |
Competitors
| Name | Revenue | Website | |
|---|---|---|---|
| Livistosp. z o.o. | $17,956,135.04 | livisto.pl | |
| Nutropharmasp. z o.o. | $13,240,122.91 | nutropharma.pl | |
| PolypharmS.A. | $13,084,716.73 | polypharm.pl | |
| Viridissp. z o.o. | $10,909,121.03 | viridisfeeds.com | |
| Diather Petrusewiczsp. k. | $7,399,375.09 | diather.pl | |
| Nutratrade Polskasp. z o.o. | $6,693,521.66 | nutratrade.pl | |
| Provital Polskasp. z o.o. | $5,805,102.40 | weareprovital.com | |
| Bestpharmasp. z o.o. | $5,786,190.68 | bestpharma.pl | |
| Steriwundsp. z o.o. | $2,832,891.51 | steriwund.pl | |
| Farmbudsp. z o.o. | $2,476,637.88 | farmbud.eu |
FAQ
Last updated: 2026-07-17